RTP Mobile Logo
RTP TV: Part VII — Non-Hodgkin Lymphoma/Chronic Lymphocytic Leukemia
Released August 2011

In this, the seventh part (originally held July 26, 2011) of our eight-part online, integrated educational course, Drs Stephanie A Gregory and John P Leonard discuss recent advances in the treatment of non-Hodgkin lymphoma/chronic lymphocytic leukemia. (Webinar)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma.

    OVERVIEW OF ACTIVITY

    Hematologic cancer includes the lymphomas, the leukemias, multiple myeloma and other related disorders such as myelodysplastic syndromes and myeloproliferative diseases, all stemming from lymphoid and myeloid progenitor cell lines. Cytotoxic chemotherapies, autologous and/or allogeneic hematopoietic stem cell transplant and biologic or molecular-targeted therapies have been the focus of treatment algorithms designed to assist clinicians in the clinical care of patients with hematologic cancer. Despite the existence of such tools, many areas of controversy persist within the academic and community settings, especially within the area of non-Hodgkin lymphoma. The recent entry of novel agents and the emergence of extensive practice-changing clinical trial data have created clinical scenarios in which multiple treatment options may be available but the optimal strategy is highly debatable. To bridge the gap between research and patient care, this CME activity will use a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians in the formulation of up-to-date and appropriate treatment strategies.

    LEARNING OBJECTIVES

    • Use case-based learning to refine or validate your current management of follicular lymphoma, mantle-cell lymphoma and chronic lymphocytic leukemia.
    • Develop a long-term treatment plan for patients receiving maintenance therapy.  
    • Counsel patients about clinical trial options investigating novel agents and strategies.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Stephanie A Gregory, MD
    The Elodia Kehm Chair of Hematology
    Professor of Medicine
    Director, Section of Hematology
    Rush University Medical Center
    Chicago, Illinois

    Advisory Committee: Amgen Inc, Cephalon Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; Speakers Bureau: Cephalon Inc.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Professor of Medicine, Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology/Biogen Idec and Millennium: The Takeda Oncology Company.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2011
    Expiration date: August 2012

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):